Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 9405 | 27.295 |
09:36 ET | 100 | 27.33 |
09:38 ET | 1700 | 27.11 |
09:39 ET | 4242 | 27.22 |
09:41 ET | 400 | 27.245 |
09:43 ET | 8035 | 26.915 |
09:45 ET | 2055 | 26.99 |
09:48 ET | 1000 | 26.835 |
09:50 ET | 1700 | 26.91 |
09:52 ET | 1198 | 26.84 |
09:54 ET | 2030 | 26.86 |
09:56 ET | 1205 | 27.01 |
09:57 ET | 200 | 27.07 |
09:59 ET | 1400 | 26.92 |
10:01 ET | 1270 | 26.91 |
10:03 ET | 300 | 26.92 |
10:06 ET | 4713 | 26.94 |
10:08 ET | 9262 | 26.89 |
10:10 ET | 1300 | 26.87 |
10:12 ET | 500 | 26.83 |
10:14 ET | 500 | 26.87 |
10:15 ET | 2181 | 26.75 |
10:17 ET | 100 | 26.78 |
10:19 ET | 350 | 26.75 |
10:21 ET | 2366 | 26.68 |
10:24 ET | 2600 | 26.79 |
10:26 ET | 1390 | 26.7 |
10:28 ET | 2100 | 26.71 |
10:30 ET | 1362 | 26.7 |
10:32 ET | 1860 | 26.635 |
10:33 ET | 2594 | 26.67 |
10:35 ET | 800 | 26.73 |
10:37 ET | 2190 | 26.7 |
10:39 ET | 115 | 26.7242 |
10:42 ET | 750 | 26.81 |
10:44 ET | 100 | 26.81 |
10:46 ET | 400 | 26.735 |
10:48 ET | 1532 | 26.675 |
10:50 ET | 850 | 26.62 |
10:51 ET | 1414 | 26.63 |
10:55 ET | 1700 | 26.62 |
10:57 ET | 400 | 26.6 |
11:00 ET | 2750 | 26.6287 |
11:02 ET | 3106 | 26.65 |
11:04 ET | 100 | 26.67 |
11:06 ET | 10697 | 26.73 |
11:08 ET | 359 | 26.67 |
11:09 ET | 453 | 26.76 |
11:11 ET | 2098 | 26.64 |
11:13 ET | 100 | 26.6 |
11:15 ET | 700 | 26.59 |
11:18 ET | 869 | 26.6 |
11:20 ET | 800 | 26.55 |
11:22 ET | 200 | 26.52 |
11:24 ET | 2242 | 26.5312 |
11:26 ET | 2900 | 26.47 |
11:27 ET | 3300 | 26.53 |
11:29 ET | 200 | 26.51 |
11:31 ET | 300 | 26.51 |
11:33 ET | 1301 | 26.54 |
11:36 ET | 214 | 26.5 |
11:38 ET | 1183 | 26.52 |
11:40 ET | 900 | 26.52 |
11:42 ET | 4730 | 26.47 |
11:44 ET | 500 | 26.46 |
11:45 ET | 300 | 26.45 |
11:47 ET | 2600 | 26.465 |
11:51 ET | 720 | 26.44 |
11:54 ET | 600 | 26.42 |
11:56 ET | 1380 | 26.45 |
11:58 ET | 300 | 26.43 |
12:00 ET | 952 | 26.46 |
12:02 ET | 2988 | 26.37 |
12:03 ET | 2200 | 26.46 |
12:05 ET | 1855 | 26.47 |
12:07 ET | 600 | 26.46 |
12:09 ET | 2221 | 26.52 |
12:12 ET | 300 | 26.525 |
12:14 ET | 4226 | 26.535 |
12:16 ET | 400 | 26.54 |
12:18 ET | 100 | 26.52 |
12:20 ET | 1962 | 26.66 |
12:21 ET | 400 | 26.67 |
12:23 ET | 1804 | 26.63 |
12:25 ET | 500 | 26.57 |
12:27 ET | 631 | 26.59 |
12:30 ET | 100 | 26.59 |
12:32 ET | 609 | 26.63 |
12:34 ET | 418 | 26.59 |
12:36 ET | 300 | 26.56 |
12:38 ET | 1256 | 26.5 |
12:39 ET | 100 | 26.47 |
12:41 ET | 1005 | 26.44 |
12:43 ET | 400 | 26.42 |
12:45 ET | 1309 | 26.45 |
12:48 ET | 700 | 26.455 |
12:50 ET | 2200 | 26.55 |
12:52 ET | 100 | 26.535 |
12:54 ET | 1300 | 26.51 |
12:56 ET | 400 | 26.45 |
12:57 ET | 100 | 26.43 |
12:59 ET | 200 | 26.37 |
01:01 ET | 800 | 26.32 |
01:03 ET | 2212 | 26.375 |
01:06 ET | 580 | 26.37 |
01:08 ET | 7000 | 26.4 |
01:10 ET | 500 | 26.44 |
01:12 ET | 600 | 26.435 |
01:14 ET | 200 | 26.435 |
01:15 ET | 4000 | 26.4925 |
01:17 ET | 700 | 26.5 |
01:19 ET | 1333 | 26.52 |
01:21 ET | 670 | 26.53 |
01:24 ET | 500 | 26.525 |
01:26 ET | 1100 | 26.52 |
01:28 ET | 3457 | 26.505 |
01:30 ET | 4746 | 26.5 |
01:32 ET | 3138 | 26.4 |
01:33 ET | 1056 | 26.36 |
01:35 ET | 600 | 26.4 |
01:37 ET | 420 | 26.34 |
01:39 ET | 1300 | 26.39 |
01:42 ET | 1350 | 26.37 |
01:44 ET | 400 | 26.35 |
01:46 ET | 1600 | 26.33 |
01:48 ET | 1481 | 26.31 |
01:50 ET | 300 | 26.31 |
01:51 ET | 532 | 26.27 |
01:53 ET | 200 | 26.27 |
01:55 ET | 100 | 26.26 |
01:57 ET | 400 | 26.26 |
02:00 ET | 3665 | 26.285 |
02:02 ET | 500 | 26.27 |
02:04 ET | 1510 | 26.345 |
02:06 ET | 600 | 26.39 |
02:08 ET | 800 | 26.405 |
02:09 ET | 200 | 26.405 |
02:11 ET | 400 | 26.43 |
02:13 ET | 500 | 26.43 |
02:15 ET | 700 | 26.415 |
02:18 ET | 1900 | 26.46 |
02:20 ET | 2200 | 26.5 |
02:24 ET | 1434 | 26.44 |
02:26 ET | 915 | 26.47 |
02:27 ET | 100 | 26.475 |
02:29 ET | 1400 | 26.52 |
02:31 ET | 800 | 26.52 |
02:33 ET | 1275 | 26.51 |
02:36 ET | 1300 | 26.53 |
02:38 ET | 200 | 26.53 |
02:40 ET | 100 | 26.52 |
02:42 ET | 1600 | 26.515 |
02:44 ET | 3190 | 26.62 |
02:45 ET | 1204 | 26.6 |
02:47 ET | 500 | 26.6 |
02:49 ET | 850 | 26.6 |
02:51 ET | 845 | 26.63 |
02:54 ET | 600 | 26.64 |
02:56 ET | 700 | 26.6 |
02:58 ET | 892 | 26.61 |
03:00 ET | 1527 | 26.65 |
03:03 ET | 300 | 26.68 |
03:05 ET | 465 | 26.675 |
03:07 ET | 1505 | 26.64 |
03:09 ET | 200 | 26.61 |
03:12 ET | 800 | 26.57 |
03:14 ET | 660 | 26.55 |
03:16 ET | 2616 | 26.64 |
03:18 ET | 800 | 26.64 |
03:20 ET | 2554 | 26.71 |
03:21 ET | 1300 | 26.77 |
03:23 ET | 455 | 26.78 |
03:25 ET | 4580 | 26.74 |
03:27 ET | 900 | 26.755 |
03:30 ET | 2200 | 26.79 |
03:32 ET | 1624 | 26.76 |
03:34 ET | 683 | 26.74 |
03:36 ET | 1512 | 26.685 |
03:38 ET | 600 | 26.68 |
03:39 ET | 1000 | 26.69 |
03:41 ET | 1000 | 26.68 |
03:43 ET | 1203 | 26.65 |
03:45 ET | 1800 | 26.64 |
03:48 ET | 200 | 26.61 |
03:50 ET | 1100 | 26.61 |
03:52 ET | 1694 | 26.62 |
03:54 ET | 2708 | 26.6 |
03:56 ET | 6161 | 26.46 |
03:57 ET | 7008 | 26.515 |
03:59 ET | 18200 | 26.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.9B | -14.1x | --- |
Avidity Biosciences Inc | 4.1B | -13.2x | --- |
Crinetics Pharmaceuticals Inc | 3.6B | -12.1x | --- |
Immunitybio Inc | 4.3B | -5.9x | --- |
Dyne Therapeutics Inc | 3.4B | -8.7x | --- |
Merus NV | 3.6B | -19.5x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.